---
title: "109 Growth-stage Biotech Investors (Nov 2026)"
last_updated: "2026-11-07"
rows: "109"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/growth-biotech-investors/"
---

# 109 growth-stage biotech investors

We list 109 growth-stage biotech investors as of November 2026: 45 have an SEC filing on file and 64 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (11), New York (7) and Massachusetts (5).

- 109 investors
- 55 with a fund filing or dated deal in the last 12 months
- $100M median fund size on file (SEC Form D, 27 firms)
- 569 named decision-makers on file

## First 25 of 109 growth-stage biotech investors

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Biotech, Healthtech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/cambridge-innovation-capital/ |
| NewVale Capital | VC firm | Boulder, CO | Growth | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/newvale-capital/ |
| Audere | VC firm | Austin, TX | Growth | Biotech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/audere/ |
| JSTAR Capital | VC firm | Austin, TX | Growth | Biotech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/jstar-capital/ |
| Highland Europe | VC firm | London, United Kingdom | Growth | Biotech, AI, Cybersecurity, SaaS | New fund, Jul 2026 | €1.1B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/highland-europe/ |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/arcventis-health-partners/ |
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Biotech, Healthtech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/claret-capital-partners/ |
| THP | VC firm | San Francisco, CA | Growth | Biotech, Healthtech, Industrial Tech, Medtech | Portfolio news, Apr 2026 | $79M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/thp/ |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Biotech, Healthtech, Medtech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/mvm-partners-llp/ |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hbm-partners-ag/ |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/andera-partners/ |
| Eckuity Capital | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/eckuity-capital/ |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/bgf/ |
| Outlier Ventures | VC firm | United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, AI, Robotics, Fintech | New deal, Oct 2026 | $500M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/outlier-ventures/ |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/madrona/ |
| 819 Capital Partners | VC firm | Deventer, Netherlands | Seed, Series A, Growth | Biotech, Healthtech, Medtech, Generalist | Portfolio news, Sep 2026 | €100M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/819-capital-partners/ |
| BroadOak Capital Partners | VC firm | Bethesda, MD | Growth | Biotech, Healthtech, Industrial Tech, SaaS | Portfolio news, Apr 2026 | $11M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/broadoak-capital-partners/ |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/sofinnova-partners/ |
| Signet Healthcare Partners | VC firm | New York, NY | Growth | Biotech, Industrial Tech, Developer Tools, Healthtech | Portfolio news, May 2025 | $300M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/signet-healthcare-partners/ |
| Agent Capital | VC firm | Waltham, MA | Seed, Growth | Biotech, Healthtech | New fund, Feb 2026 | $100M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/agent-capital/ |
| Cambridge Capital Group | Angel network | Cambridge, United Kingdom | Seed, Growth | Biotech, Industrial Tech, AI, Developer Tools | New fund, Oct 2026 | £50M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/cambridge-capital-group/ |
| Archangels | Angel network | Edinburgh, United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, Media, Deep Tech, Healthtech | Portfolio news, Nov 2026 | £10M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/archangels/ |
| SHS Capital | Fund manager | Tübingen, Germany | Growth | Biotech, Healthtech, Medtech | New fund, Feb 2026 | €270M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/shs-gesellschaft-fur-beteiligungsmanagement-mbh/ |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/wellington-partners/ |

You are seeing 25 of 109. The full list adds 84 more investors and 569 named decision-makers.

Get all 109 investors and 569 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/growth-biotech-investors
This page: https://theinvestordatabase.com/lists/growth-biotech-investors/

## Method and limits
- Source: 45 of the 109 rows carry an SEC filing (Form D or Form ADV). All 109 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 109 rows: stage 109, sector 109, fund size 74, website 109. In the paid file: named decision-makers on 99 rows, firm email on 60, LinkedIn page on 72, check size on 28.

## Questions
### How many growth-stage biotech investors are there?
We list 109 as of November 2026. 55 of the 109 have a fund filing or a dated deal in the last 12 months.

### Which growth-stage biotech investors raised a new fund in the last 12 months?
16 of the 109 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), K5 Global (Oct 2026) and NewVale Capital (Oct 2026).

### What is the typical fund size of growth-stage biotech investors?
The median fund size on file for this list is $100M, across the 27 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 82 do not disclose a size there.

### How do I contact growth-stage biotech investors?
The paid file holds 569 named decision-makers across 99 of these 109 and a firm email for 60. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on growth-stage biotech investors come from?
45 of the 109 rows have an SEC filing on file (Form D or Form ADV) and 64 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.